- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
WellPoint PBM business for sale
WellPoint decision to sell off its PBM business is seen by experts as good, strategic move for the health insurer.
WellPoint has put its pharmacy benefits management (PBM) business up for auction, which is likely to attract interest from CVS Caremark, Medco Health Solutions Inc. and Express Scripts Inc., among others.
Wellpoint’s decision to place their PBM up for auction is a good strategic move, believes Robert Taketomo, PharmD, MBA, president and CEO of Ventegra in La Jolla, Calif. “The PBM industry has been one of the most profitable industry segments and the stocks still trade at relatively high valuations. Loss of PBM functionality should not hurt Wellpoint if they still maintain control of the key pharmacy and medical decisions.”
According to Clive Riddle, president and founder of MCOL, a provider of business-to-business health management and managed care resources in Modesto, Calif., many large health plans have in-house PBMs, and “there is often intense pressure from the analyst and investor community to imitate such initiatives.” It is unlikely that WellPoint will be the only plan to go down this path in the near future".
The sale of WellPoint's PBM business, the fourth-largest in the United States, is said to be worth anywhere from less than $1 billion to five times that amount.
A Conversation With Greg Baker, RPh, CEO of AffirmedRx
March 31st 2024Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.
Read More
Extending the Capabilities of the EHR Through Automation
August 2nd 2023Welcome back to another episode of "Tuning In to the C-Suite," where Briana Contreras, an editor of Managed Healthcare Executive, had the pleasure of chatting with Cindy Gaines, chief clinical transformation officer at Lumeon.
Listen
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More
The deliberate disconnection of Change Healthcare to ring fence a cyberattack entered its seventh day today. Prescribers are finding ways to get pharmacy claims processed, and UnitedHealth Group says disruption to the dispensing of prescriptions has been minimal. But independent pharmacies want more information and protection from financial consequences from pharmacy benefit managers.
Read More
